Comparative Pharmacology
Head-to-head clinical analysis: BENZONATATE versus DEXTROMETHORPHAN POLISTIREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZONATATE versus DEXTROMETHORPHAN POLISTIREX.
BENZONATATE vs DEXTROMETHORPHAN POLISTIREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
100 mg to 200 mg orally three times daily as needed for cough.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Category A/B
Category C
Antitussive
Antitussive